US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

Sporadic inclusion body myositis (sIBM) presents with a characteristic ... pathways might prove helpful in arresting disease progression. sIBM is often misdiagnosed as polymyositis or other ...

Inclusion body myositis (IBM) is the most prevalent muscle-wasting disease ... highlights the need for a core outcome set to consistently assess treatment response and disease progression in IBM, ...

Myopathic (myo = muscle, pathy = disease) conditions can include polymyositis, dermatomyositis, inclusion body myositis, and various myopathies ... including the heart. The rate of progression of the ...

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and develop a platform of off-the-shelf neuron replacement therapies for neurological ...

In trials, the PPAR agonists were effective in reducing progression of PBC ... a pivotal trial of ulviprubart for rare disease inclusion body myositis (IBM).

The Boston-area company’s previous raises were also aimed at getting its investigational antibody treatment for inclusion ...

Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors. Abcuro announced that it has obtained $200 million in Series C financing, led by ...

Abcuro Inc. has raised a $200 million Series C financing to fund late-stage development and support commercial launch ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Proceeds to support completion of the registrational Phase 2/3 MUSCLE trial of ulviprubart in inclusion body myositis, BLA filing, and commercial launch preparation NEWTON, Mass.--(BUSINESS ...

sIBM is a complex disorder, the underlying cause of which is unclear. The observation that the intact muscle fibers are invaded by T lymphocytes, whereas the vacuolated fibers lack T-cell ...